Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
Objective: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG). Materials and Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed w...
Saved in:
Main Authors: | , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2022
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/75110 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.75110 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.751102022-08-04T11:39:35Z Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma Naris Kitnarong Janyawassamon Kittipiriyakul Anuwat Jiravarnsirikul Siriraj Hospital Medicine Objective: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG). Materials and Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2 weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needling were performed after TMC if indicated. Best corrected visual acuity (BCVA), intraocular pressure (IOP), surgical complications, and number of anti-glaucoma medications were collected. Results: Five eyes from 5 consecutive patients were included. Two eyes had proliferative diabetic retinopathy (PDR), 2 central retinal vein occlusion, and 1 ocular ischemic syndrome (OIS) (mean initial IOP: 46.8±6.8 mmHg). NVI regression occurred in one eye after PRP alone, and in one eye after PRP and IVA resulting in a good IOP control with topical medical therapy. The other 3 underwent TMC. The preoperative IOP was 34 (OIS), 54 (PDR), and 50 (PDR) mmHg. The 3-month postoperative IOP decreased to 8, 8, and 4 mmHg, respectively, and to 21, 10, and 6 mmHg, respectively, at the last visit. Only the one OIS eye required postoperative topical IOP-lowering medications. Final BCVA was improved, unchanged, and decreased in 2, 2, and 1 eye, respectively. No intraoperative/postoperative complications or NVI recurrence were observed (mean follow-up: 10.7 months). Conclusion: Intravitreal aflibercept was shown to be a potentially effective additional treatment to PRP and TMC in patients with NVG. 2022-08-04T04:39:35Z 2022-08-04T04:39:35Z 2022-01-01 Article Siriraj Medical Journal. Vol.74, No.1 (2022), 27-33 10.33192/SMJ.2022.4 22288082 2-s2.0-85123535944 https://repository.li.mahidol.ac.th/handle/123456789/75110 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85123535944&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Naris Kitnarong Janyawassamon Kittipiriyakul Anuwat Jiravarnsirikul Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma |
description |
Objective: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG). Materials and Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2 weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needling were performed after TMC if indicated. Best corrected visual acuity (BCVA), intraocular pressure (IOP), surgical complications, and number of anti-glaucoma medications were collected. Results: Five eyes from 5 consecutive patients were included. Two eyes had proliferative diabetic retinopathy (PDR), 2 central retinal vein occlusion, and 1 ocular ischemic syndrome (OIS) (mean initial IOP: 46.8±6.8 mmHg). NVI regression occurred in one eye after PRP alone, and in one eye after PRP and IVA resulting in a good IOP control with topical medical therapy. The other 3 underwent TMC. The preoperative IOP was 34 (OIS), 54 (PDR), and 50 (PDR) mmHg. The 3-month postoperative IOP decreased to 8, 8, and 4 mmHg, respectively, and to 21, 10, and 6 mmHg, respectively, at the last visit. Only the one OIS eye required postoperative topical IOP-lowering medications. Final BCVA was improved, unchanged, and decreased in 2, 2, and 1 eye, respectively. No intraoperative/postoperative complications or NVI recurrence were observed (mean follow-up: 10.7 months). Conclusion: Intravitreal aflibercept was shown to be a potentially effective additional treatment to PRP and TMC in patients with NVG. |
author2 |
Siriraj Hospital |
author_facet |
Siriraj Hospital Naris Kitnarong Janyawassamon Kittipiriyakul Anuwat Jiravarnsirikul |
format |
Article |
author |
Naris Kitnarong Janyawassamon Kittipiriyakul Anuwat Jiravarnsirikul |
author_sort |
Naris Kitnarong |
title |
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma |
title_short |
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma |
title_full |
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma |
title_fullStr |
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma |
title_full_unstemmed |
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma |
title_sort |
aflibercept as adjunctive treatment for filtration surgery in neovascular glaucoma |
publishDate |
2022 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/75110 |
_version_ |
1763498126038007808 |